세계 신경 교종 치료 시장

Global Glioma Treatment Market to Reach US$8.3 Billion by 2030

The global market for Glioma Treatment estimated at US$4.9 Billion in the year 2023, is expected to reach US$8.3 Billion by 2030, growing at a CAGR of 8.0% over the analysis period 2023-2030. Surgery, one of the segments analyzed in the report, is expected to record a 6.8% CAGR and reach US$2.9 Billion by the end of the analysis period. Growth in the Chemotherapy segment is estimated at 7.0% CAGR over the analysis period.

The U.S. Market is Estimated at US$1.3 Billion While China is Forecast to Grow at 7.7% CAGR

The Glioma Treatment market in the U.S. is estimated at US$1.3 Billion in the year 2023. China, the world's second largest economy, is forecast to reach a projected market size of US$1.3 Billion by the year 2030 trailing a CAGR of 7.7% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 7.1% and 6.9% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 6.5% CAGR.

Global Glioma Treatment Market - Key Trends and Drivers Summarized

Gliomas are a diverse group of brain tumors originating from glial cells, which support and protect neurons in the central nervous system. Treatment of gliomas varies significantly based on the tumor's grade, location, and genetic characteristics. High-grade gliomas, such as glioblastomas, are particularly aggressive and challenging to treat, necessitating a multimodal approach that typically includes surgery, radiation therapy, and chemotherapy. Temozolomide, an oral chemotherapy drug, is commonly used in combination with radiotherapy due to its ability to penetrate the blood-brain barrier and improve patient outcomes. Recent advancements in molecular profiling have led to more personalized treatment strategies, with targeted therapies and immunotherapies offering new hope for patients with specific genetic mutations.

Innovative treatments for glioma are being driven by breakthroughs in biotechnology and a deeper understanding of tumor biology. Precision medicine approaches, which tailor treatments based on an individual’s genetic makeup, are increasingly employed to enhance efficacy and minimize side effects. For instance, therapies targeting specific mutations such as IDH1/2 inhibitors and EGFR inhibitors are under active investigation in clinical trials. Additionally, immunotherapy, including checkpoint inhibitors and CAR-T cell therapy, has shown promise in harnessing the body’s immune system to combat glioma cells. Advances in drug delivery systems, such as convection-enhanced delivery and nanoparticle-based carriers, are also improving the targeted delivery of chemotherapeutic agents, thereby increasing their concentration at the tumor site while reducing systemic toxicity.

The growth in the glioma treatment market is driven by several factors. Key among these is the increasing incidence of gliomas and the significant unmet medical need for effective therapies. Technological advancements in molecular diagnostics have enabled the identification of actionable genetic mutations, driving the adoption of targeted therapies. The expanding field of immunotherapy and its success in other cancer types have spurred investment in glioma-specific immune-based treatments. Additionally, the development of novel drug delivery mechanisms has expanded the therapeutic landscape by improving the precision and efficacy of existing treatments. Government and private sector funding for brain cancer research, along with regulatory incentives such as orphan drug designations, further propel market growth. Moreover, growing awareness of glioma symptoms and advancements in imaging technologies contribute to earlier diagnosis and intervention, improving treatment outcomes and driving demand for advanced therapies. Collectively, these factors are fostering a dynamic and rapidly evolving market for glioma treatments.

Select Competitors (Total 86 Featured) -

• Amgen Inc.
• Amneal Pharmaceuticals, LLC
• Ariceum Therapeutics GmbH
• Azurity Pharmaceuticals, Inc. (Gliade)
• Bristol-Myers Squibb Company
• CNS Therapeutics, Inc.
• Denovo Biopharma LLC
• Elekta
• F. Hoffmann-La Roche Ltd.,
• ITM Isotope Technologies Munich SE
• Karyopharm Therapeutics, Inc.
• Lantern Pharma Inc.
• Novartis AG
• Novocure
• VBI Vaccines Inc.;

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

• 1. MARKET OVERVIEW
  • Influencer Market Insights
  • Global Economic Update
  • Glioma Treatment - Global Key Competitors Percentage Market Share in 2024 (E)
  • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E)
• 2. FOCUS ON SELECT PLAYERS
• 3. MARKET TRENDS & DRIVERS
  • Rising Incidence of Gliomas Spurs Demand for Effective Therapies
  • Technological Advancements in Molecular Diagnostics Propel Growth
  • Precision Medicine Approaches Expand Addressable Market Opportunity
  • Development of Targeted Therapies Strengthens Business Case for Personalized Treatment
  • Increasing Adoption of Immunotherapy Drives Market Expansion
  • Novel Drug Delivery Systems Generate New Market Opportunities
  • Advances in Imaging Technologies Drive Early Diagnosis and Intervention
  • Growing Awareness of Glioma Symptoms Spurs Demand for Advanced Therapies
  • Here's How Molecular Profiling Enhances Treatment Personalization
  • Expanding Field of Genetic Research Generates Opportunities for Novel Treatments
  • Increasing Use of AI and Machine Learning in Drug Discovery Spurs Growth
  • Advances in Biomarker Identification Generate New Avenues for Targeted Therapy
  • Integration of Telemedicine and Remote Monitoring Technologies Expands Access to Care
  • Rising Investment in Oncology Propels Market Expansion for Glioma Treatments
• 4. GLOBAL MARKET PERSPECTIVE
  • TABLE 1: World Glioma Treatment Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030
  • TABLE 2: World Recent Past, Current & Future Analysis for Glioma Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • TABLE 3: World Historic Review for Glioma Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 4: World 16-Year Perspective for Glioma Treatment by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2014, 2024 & 2030
  • TABLE 5: World Recent Past, Current & Future Analysis for Surgery by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • TABLE 6: World Historic Review for Surgery by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 7: World 16-Year Perspective for Surgery by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
  • TABLE 8: World Recent Past, Current & Future Analysis for Chemotherapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • TABLE 9: World Historic Review for Chemotherapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 10: World 16-Year Perspective for Chemotherapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
  • TABLE 11: World Recent Past, Current & Future Analysis for Radiation Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • TABLE 12: World Historic Review for Radiation Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 13: World 16-Year Perspective for Radiation Therapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
  • TABLE 14: World Recent Past, Current & Future Analysis for Targeted Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • TABLE 15: World Historic Review for Targeted Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 16: World 16-Year Perspective for Targeted Therapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
  • TABLE 17: World Recent Past, Current & Future Analysis for Other Treatment Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • TABLE 18: World Historic Review for Other Treatment Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 19: World 16-Year Perspective for Other Treatment Types by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030

III. MARKET ANALYSIS

• UNITED STATES
  • Glioma Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2024 (E)
  • TABLE 20: USA Recent Past, Current & Future Analysis for Glioma Treatment by Treatment Type - Surgery, Chemotherapy, Radiation Therapy, Targeted Therapy and Other Treatment Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 21: USA Historic Review for Glioma Treatment by Treatment Type - Surgery, Chemotherapy, Radiation Therapy, Targeted Therapy and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 22: USA 16-Year Perspective for Glioma Treatment by Treatment Type - Percentage Breakdown of Value Sales for Surgery, Chemotherapy, Radiation Therapy, Targeted Therapy and Other Treatment Types for the Years 2014, 2024 & 2030
• CANADA
  • TABLE 23: Canada Recent Past, Current & Future Analysis for Glioma Treatment by Treatment Type - Surgery, Chemotherapy, Radiation Therapy, Targeted Therapy and Other Treatment Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 24: Canada Historic Review for Glioma Treatment by Treatment Type - Surgery, Chemotherapy, Radiation Therapy, Targeted Therapy and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 25: Canada 16-Year Perspective for Glioma Treatment by Treatment Type - Percentage Breakdown of Value Sales for Surgery, Chemotherapy, Radiation Therapy, Targeted Therapy and Other Treatment Types for the Years 2014, 2024 & 2030
• JAPAN
  • Glioma Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2024 (E)
  • TABLE 26: Japan Recent Past, Current & Future Analysis for Glioma Treatment by Treatment Type - Surgery, Chemotherapy, Radiation Therapy, Targeted Therapy and Other Treatment Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 27: Japan Historic Review for Glioma Treatment by Treatment Type - Surgery, Chemotherapy, Radiation Therapy, Targeted Therapy and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 28: Japan 16-Year Perspective for Glioma Treatment by Treatment Type - Percentage Breakdown of Value Sales for Surgery, Chemotherapy, Radiation Therapy, Targeted Therapy and Other Treatment Types for the Years 2014, 2024 & 2030
• CHINA
  • Glioma Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2024 (E)
  • TABLE 29: China Recent Past, Current & Future Analysis for Glioma Treatment by Treatment Type - Surgery, Chemotherapy, Radiation Therapy, Targeted Therapy and Other Treatment Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 30: China Historic Review for Glioma Treatment by Treatment Type - Surgery, Chemotherapy, Radiation Therapy, Targeted Therapy and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 31: China 16-Year Perspective for Glioma Treatment by Treatment Type - Percentage Breakdown of Value Sales for Surgery, Chemotherapy, Radiation Therapy, Targeted Therapy and Other Treatment Types for the Years 2014, 2024 & 2030
• EUROPE
  • Glioma Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2024 (E)
  • TABLE 32: Europe Recent Past, Current & Future Analysis for Glioma Treatment by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • TABLE 33: Europe Historic Review for Glioma Treatment by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 34: Europe 16-Year Perspective for Glioma Treatment by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2014, 2024 & 2030
  • TABLE 35: Europe Recent Past, Current & Future Analysis for Glioma Treatment by Treatment Type - Surgery, Chemotherapy, Radiation Therapy, Targeted Therapy and Other Treatment Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 36: Europe Historic Review for Glioma Treatment by Treatment Type - Surgery, Chemotherapy, Radiation Therapy, Targeted Therapy and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 37: Europe 16-Year Perspective for Glioma Treatment by Treatment Type - Percentage Breakdown of Value Sales for Surgery, Chemotherapy, Radiation Therapy, Targeted Therapy and Other Treatment Types for the Years 2014, 2024 & 2030
• FRANCE
  • Glioma Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2024 (E)
  • TABLE 38: France Recent Past, Current & Future Analysis for Glioma Treatment by Treatment Type - Surgery, Chemotherapy, Radiation Therapy, Targeted Therapy and Other Treatment Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 39: France Historic Review for Glioma Treatment by Treatment Type - Surgery, Chemotherapy, Radiation Therapy, Targeted Therapy and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 40: France 16-Year Perspective for Glioma Treatment by Treatment Type - Percentage Breakdown of Value Sales for Surgery, Chemotherapy, Radiation Therapy, Targeted Therapy and Other Treatment Types for the Years 2014, 2024 & 2030
• GERMANY
  • Glioma Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2024 (E)
  • TABLE 41: Germany Recent Past, Current & Future Analysis for Glioma Treatment by Treatment Type - Surgery, Chemotherapy, Radiation Therapy, Targeted Therapy and Other Treatment Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 42: Germany Historic Review for Glioma Treatment by Treatment Type - Surgery, Chemotherapy, Radiation Therapy, Targeted Therapy and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 43: Germany 16-Year Perspective for Glioma Treatment by Treatment Type - Percentage Breakdown of Value Sales for Surgery, Chemotherapy, Radiation Therapy, Targeted Therapy and Other Treatment Types for the Years 2014, 2024 & 2030
• ITALY
  • TABLE 44: Italy Recent Past, Current & Future Analysis for Glioma Treatment by Treatment Type - Surgery, Chemotherapy, Radiation Therapy, Targeted Therapy and Other Treatment Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 45: Italy Historic Review for Glioma Treatment by Treatment Type - Surgery, Chemotherapy, Radiation Therapy, Targeted Therapy and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 46: Italy 16-Year Perspective for Glioma Treatment by Treatment Type - Percentage Breakdown of Value Sales for Surgery, Chemotherapy, Radiation Therapy, Targeted Therapy and Other Treatment Types for the Years 2014, 2024 & 2030
• UNITED KINGDOM
  • Glioma Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2024 (E)
  • TABLE 47: UK Recent Past, Current & Future Analysis for Glioma Treatment by Treatment Type - Surgery, Chemotherapy, Radiation Therapy, Targeted Therapy and Other Treatment Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 48: UK Historic Review for Glioma Treatment by Treatment Type - Surgery, Chemotherapy, Radiation Therapy, Targeted Therapy and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 49: UK 16-Year Perspective for Glioma Treatment by Treatment Type - Percentage Breakdown of Value Sales for Surgery, Chemotherapy, Radiation Therapy, Targeted Therapy and Other Treatment Types for the Years 2014, 2024 & 2030
• REST OF EUROPE
  • TABLE 50: Rest of Europe Recent Past, Current & Future Analysis for Glioma Treatment by Treatment Type - Surgery, Chemotherapy, Radiation Therapy, Targeted Therapy and Other Treatment Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 51: Rest of Europe Historic Review for Glioma Treatment by Treatment Type - Surgery, Chemotherapy, Radiation Therapy, Targeted Therapy and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 52: Rest of Europe 16-Year Perspective for Glioma Treatment by Treatment Type - Percentage Breakdown of Value Sales for Surgery, Chemotherapy, Radiation Therapy, Targeted Therapy and Other Treatment Types for the Years 2014, 2024 & 2030
• ASIA-PACIFIC
  • Glioma Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2024 (E)
  • TABLE 53: Asia-Pacific Recent Past, Current & Future Analysis for Glioma Treatment by Treatment Type - Surgery, Chemotherapy, Radiation Therapy, Targeted Therapy and Other Treatment Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 54: Asia-Pacific Historic Review for Glioma Treatment by Treatment Type - Surgery, Chemotherapy, Radiation Therapy, Targeted Therapy and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 55: Asia-Pacific 16-Year Perspective for Glioma Treatment by Treatment Type - Percentage Breakdown of Value Sales for Surgery, Chemotherapy, Radiation Therapy, Targeted Therapy and Other Treatment Types for the Years 2014, 2024 & 2030
• REST OF WORLD
  • TABLE 56: Rest of World Recent Past, Current & Future Analysis for Glioma Treatment by Treatment Type - Surgery, Chemotherapy, Radiation Therapy, Targeted Therapy and Other Treatment Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 57: Rest of World Historic Review for Glioma Treatment by Treatment Type - Surgery, Chemotherapy, Radiation Therapy, Targeted Therapy and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 58: Rest of World 16-Year Perspective for Glioma Treatment by Treatment Type - Percentage Breakdown of Value Sales for Surgery, Chemotherapy, Radiation Therapy, Targeted Therapy and Other Treatment Types for the Years 2014, 2024 & 2030

IV. COMPETITION